<DOC>
	<DOCNO>NCT00028691</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . It yet know chlorambucil effective radiation therapy treat follicular lymphoma . PURPOSE : Randomized phase III trial compare effectiveness chlorambucil radiation therapy treat patient stage III stage IV follicular lymphoma previously treat .</brief_summary>
	<brief_title>Chlorambucil Compared With Radiation Therapy Treating Patients With Previously Untreated Stage III Stage IV Follicular Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect chlorambucil v involved-field radiotherapy progression-free survival patient previously untreated stage III IV follicular lymphoma . - Compare complete partial remission rate overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral chlorambucil day 1-5 . Treatment repeat every 4 week 6-8 course absence disease progression unacceptable toxicity . - Arm II : Patients undergo radiotherapy day 1 3 ( day 15 17 split course ) . Quality life assess baseline , prior course 3 , 6 , 8 ( arm I ) , 4-6 week study . Patients follow 4-6 week , 3-4 month ( arm I ) , 3 month 6 month ( arm II ) , 11 , 12 , 15 , 18 , 21 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 444 patient ( 222 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follicular lymphoma Stage III IV disease Grades I , II , III Previously untreated disease Nodal extranodal sit Bidimensionally measurable disease physical examination diagnostic imaging No CNS orbital nonHodgkin 's lymphoma localization PATIENT CHARACTERISTICS : Age : 18 ( patient EORTC center ) 65 ( patient HOVON center ) Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 6.0 g/dL Hepatic : Not specify Renal : Not specify Cardiovascular : No severe cardiac disease would preclude study treatment Pulmonary : No severe pulmonary disease would preclude study treatment Other : HIV negative No severe neurologic , psychiatric , metabolic disease would preclude study treatment No prior malignancy except basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent systemic corticosteroid , include dexamethasone nausea vomit palliation ( inhalation topical corticosteroid allow ) Radiotherapy : No concurrent elective radiotherapy adjacent negative lymph node Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>